TargetBeta
AURKB
aurora kinase B · also Aik2, IPL1, AurB, AIM-1 · Protein phosphatase 1 regulatory subunits
1 program in company-led studies act on AURKB, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| chiauranibrule | Chipscreen Biosciences | phase 3 | 154 running | FLT1, FLT4, KDR | ChEMBL |
Conditions their studies are in
- Lymphoma, Non-Hodgkin, 1 program
- Ovarian Neoplasms, 1 program
- Sarcoma, 1 program
- Small Cell Lung Carcinoma, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 28, 2027chiauranib · Chipscreen Biosciences · phase 3 · NCT06492915
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.